Leaning On The Knobs

I still remember sitting in a conference room in D.C. years ago, listening to a CMS official explain – with a perfectly straight face – that a 0.5% rate increase was “quite generous given the fiscal environment.” The insurers in the room did a great job of not laughing.

Fast-forward to today, and Humana (HUM) is staring at a 0.09% “raise” on its core Medicare Advantage business while medical trend runs in the mid-single digits.

For a diversified giant like UnitedHealth (UNH), that’s annoying. For Humana, which lives and dies on Medicare Advantage, it’s a crisis.

Humana has spent the last decade turning itself into the purest play on Medicare Advantage in the public markets. More than four-fifths of its revenue now ties back to MA.

That was a brilliant trade while CMS was nudging rates higher, quality bonuses were rich, and risk-adjustment models rewarded aggressive coding.

The flywheel was elegant: design richer benefits, attract better-risk members, hit 4- and 5-star ratings, collect bonus payments, reinvest in benefits, and watch the stock rerate.

The problem isn’t that the story was wrong; it’s that the cycle turned.

The first hit came from Star Ratings. Humana managed to go from having the majority of its MA members in plans rated 4 stars or higher to having most of them outside that club in one swoop.

That matters because those ratings drive bonus payments that can add hundreds of dollars per member per year in revenue, effectively free margin if you run the operation well. Lose those stars, and suddenly you’re missing billions in high-margin dollars over a multiyear period.

You can claw some back with operational fixes, but you don’t fix a rating year overnight; CMS grades you on a rolling basis, and once you’re in the penalty box, you live there for a while.

Layer on the latest rate notice, and the picture gets uglier. CMS has basically told MA plans: we see your medical cost trend, we see your coding intensity, and we’re not going to chase it with matching price.

A 0.09% payment “increase” against something like 5% cost growth and higher utilization is a de facto cut.

At the same time, the new risk-adjustment model pushes down the value of some of the conditions that plans have been very enthusiastic about documenting.

Translation: the gap between what Humana gets paid per member and what it spends on that member is compressing from both ends.

In a business built on managing that spread, you don’t need many percentage points to go missing before your margin structure looks very different.

The Street has noticed. Humana’s multiple has deflated from a growth-franchise premium to something closer to a regulated utility with an earnings problem.

UnitedHealth and Elevance (ELV) can absorb this sort of CMS sting in a broader mix of commercial, Medicaid, and other services revenue. Humana doesn’t have that luxury.

It has some nice assets in CenterWell clinics and home health, but they don’t move the needle yet when MA margins are under coordinated assault from rates, Stars, and utilization.

There is a path out, but it is not painless and it’s definitely not fast.

Humana can respond the way every insurer eventually does when regulators squeeze: reprice plans in the next bid cycle, trim benefits, raise premiums, narrow networks, and chase a more disciplined membership mix.

That will help margins, but it risks membership losses and ceding share to competitors willing to run a bit hotter on profitability.

At the same time, management has to repair Star Ratings, which is a multi-year operational project involving everything from medication adherence programs to customer service metrics.

After all, everyone loves to plug “ratings recovery” into models as if it’s a switch. In reality, it’s trench work.

The more interesting question for an investor is whether you’re being paid enough to wait for that repair job.

On the positive side, the demographic backdrop is still excellent. The senior population is growing, MA penetration keeps grinding higher, and both parties in Washington remain broadly supportive of the program in structure, if not in margins.

This isn’t a melting-ice-cube industry, but it is a growing one with a temporarily broken spread. If Humana can stabilize Stars, get a handle on utilization, and reprice smartly into 2025–2026, today’s valuation may look like an overreaction in hindsight.

On the other hand, you have to respect path dependency. CMS has clearly signaled that it wants less exuberant profitability in MA, and it can keep leaning on the knobs: rates, risk scores, and bonus mechanics.

Humana needs at least two of those three to break its way over the next couple of years to rebuild the old economics. That’s possible, but it’s not the kind of setup where you bet the ranch and check back in five years.

This is one where you size the position modestly, watch each rate notice and Star Ratings update like a hawk, and assume a fair amount of earnings volatility along the way.

So yes, the long-term story of Medicare Advantage as a structurally attractive business is intact. But for Humana, the near-term story is that the spreadsheet in Baltimore has found religion on margins.

And if you ever forget who really sets the rules in this game, just remember that “generous” 0.09% pay raise and the very expensive lesson it’s teaching one very concentrated insurer.